Literature DB >> 20028966

RAGE supports parathyroid hormone-induced gains in femoral trabecular bone.

Binu K Philip1, Paul J Childress, Alexander G Robling, Aaron Heller, Peter P Nawroth, Angelika Bierhaus, Joseph P Bidwell.   

Abstract

Parathyroid hormone (PTH) restores bone mass to the osteopenic skeleton, but significant questions remain as to the underlying mechanisms. The receptor for advanced glycation end products (RAGE) is a multiligand receptor of the immunoglobulin superfamily; however, recent studies indicate a role in bone physiology. We investigated the significance of RAGE to hormone-induced increases in bone by treating 10-wk-old female Rage-knockout (KO) and wild-type (WT) mice with human PTH-(1-34) at 30 microg.kg(-1).day(-1) or vehicle control, 7 days/wk, for 7 wk. PTH produced equivalent relative gains in bone mineral density (BMD) and bone mineral content (BMC) throughout the skeleton in both genotypes. PTH-mediated relative increases in cortical area of the midshaft femur were not compromised in the null mice. However, the hormone-induced gain in femoral cancellous bone was significantly attenuated in Rage-KO mice. The loss of RAGE impaired PTH-mediated increases in femoral cancellous bone volume, connectivity density, and trabecular number but did not impact increases in trabecular thickness or decreases in trabecular spacing. Disabling RAGE reduced femoral expression of bone formation genes, but their relative PTH-responsiveness was not impaired. Neutralizing RAGE did not attenuate vertebral cancellous bone response to hormone. Rage-null mice exhibited an attenuated accrual rate of bone mass, with the exception of the spine, and an enhanced accrual rate of fat mass. We conclude that RAGE is necessary for key aspects of the skeleton's response to anabolic PTH. Specifically, RAGE is required for hormone-mediated improvement of femoral trabecular architecture but not intrinsically necessary for increasing cortical thickness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028966      PMCID: PMC2838526          DOI: 10.1152/ajpendo.00564.2009

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  36 in total

1.  Quantification of age-related changes in the structure model type and trabecular thickness of human tibial cancellous bone.

Authors:  M Ding; I Hvid
Journal:  Bone       Date:  2000-03       Impact factor: 4.398

2.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line.

Authors:  R Constien; A Forde; B Liliensiek; H J Gröne; P Nawroth; G Hämmerling; B Arnold
Journal:  Genesis       Date:  2001-05       Impact factor: 2.487

Review 3.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

4.  Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice.

Authors:  E Lalla; I B Lamster; M Feit; L Huang; A Spessot; W Qu; T Kislinger; Y Lu; D M Stern; A M Schmidt
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis).

Authors:  C P Jerome; D B Burr; T Van Bibber; J M Hock; R Brommage
Journal:  Bone       Date:  2001-02       Impact factor: 4.398

6.  Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.

Authors:  D W Dempster; F Cosman; E S Kurland; H Zhou; J Nieves; L Woelfert; E Shane; K Plavetić; R Müller; J Bilezikian; R Lindsay
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

Review 7.  Teriparatide: a review of its use in osteoporosis.

Authors:  Stephanie K A Blick; Sohita Dhillon; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE.

Authors:  Zheng Zhou; Jun-Yan Han; Cai-Xia Xi; Jian-Xin Xie; Xu Feng; Cong-Yi Wang; Lin Mei; Wen-Cheng Xiong
Journal:  J Bone Miner Res       Date:  2008-07       Impact factor: 6.741

Review 9.  Fat targets for skeletal health.

Authors:  Masanobu Kawai; Maureen J Devlin; Clifford J Rosen
Journal:  Nat Rev Rheumatol       Date:  2009-05-26       Impact factor: 20.543

Review 10.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Authors:  Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
Journal:  J Transl Med       Date:  2009-03-17       Impact factor: 5.531

View more
  14 in total

1.  The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions.

Authors:  Yasuhiro Hamada; Sohei Kitazawa; Riko Kitazawa; Keiji Kono; Shunsuke Goto; Hirotaka Komaba; Hideki Fujii; Yasuhiko Yamamoto; Hiroshi Yamamoto; Makoto Usami; Masafumi Fukagawa
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

2.  Immortalization and characterization of osteoblast cell lines generated from wild-type and Nmp4-null mouse bone marrow stromal cells using murine telomerase reverse transcriptase (mTERT).

Authors:  Marta B Alvarez; Paul Childress; Binu K Philip; Rita Gerard-O'Riley; Michael Hanlon; Brittney-Shea Herbert; Alexander G Robling; Fredrick M Pavalko; Joseph P Bidwell
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

3.  Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice.

Authors:  Hannah M Davis; Alyson L Essex; Sinai Valdez; Padmini J Deosthale; Mohammad W Aref; Matthew R Allen; Andrea Bonetto; Lilian I Plotkin
Journal:  Bone       Date:  2019-04-24       Impact factor: 4.398

4.  Nmp4/CIZ suppresses the response of bone to anabolic parathyroid hormone by regulating both osteoblasts and osteoclasts.

Authors:  Paul Childress; Binu K Philip; Alexander G Robling; Angela Bruzzaniti; Melissa A Kacena; Nicoletta Bivi; Lilian I Plotkin; Aaron Heller; Joseph P Bidwell
Journal:  Calcif Tissue Int       Date:  2011-05-24       Impact factor: 4.333

5.  The high-mobility group box-1 nuclear factor mediates retinal injury after ischemia reperfusion.

Authors:  Galina Dvoriantchikova; Eleut Hernandez; Jeff Grant; Andrea Rachelle C Santos; Huan Yang; Dmitry Ivanov
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-09       Impact factor: 4.799

6.  Dietary calcium intake and genetics have site-specific effects on peak trabecular bone mass and microarchitecture in male mice.

Authors:  Krittikan Chanpaisaeng; Perla C Reyes Fernandez; James C Fleet
Journal:  Bone       Date:  2019-05-09       Impact factor: 4.398

7.  The Load-Bearing Mechanosome Revisited.

Authors:  Joseph P Bidwell; Fredrick M Pavalko
Journal:  Clin Rev Bone Miner Metab       Date:  2010-11-11

8.  Guidelines for Dual Energy X-Ray Absorptiometry Analysis of Trabecular Bone-Rich Regions in Mice: Improved Precision, Accuracy, and Sensitivity for Assessing Longitudinal Bone Changes.

Authors:  Jiayu Shi; Soonchul Lee; Michael Uyeda; Justine Tanjaya; Jong Kil Kim; Hsin Chuan Pan; Patricia Reese; Louis Stodieck; Andy Lin; Kang Ting; Jin Hee Kwak; Chia Soo
Journal:  Tissue Eng Part C Methods       Date:  2016-04-15       Impact factor: 3.056

Review 9.  RAGE Signaling in Skeletal Biology.

Authors:  Lilian I Plotkin; Alyson L Essex; Hannah M Davis
Journal:  Curr Osteoporos Rep       Date:  2019-02       Impact factor: 5.096

10.  High mobility group box 1 protein regulates osteoclastogenesis through direct actions on osteocytes and osteoclasts in vitro.

Authors:  Hannah M Davis; Sinai Valdez; Leland Gomez; Peter Malicky; Fletcher A White; Mark A Subler; Jolene J Windle; Joseph P Bidwell; Angela Bruzzaniti; Lilian I Plotkin
Journal:  J Cell Biochem       Date:  2019-05-20       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.